Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2187-2194

  Tsurusaki, Toshifumi ^a   Koji, Takehiko ^a   Sakai, Hideki ^a   Kanetake, Hiroshi ^a   Saito, Yutaka ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURVIVAL; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; DIMERIZATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; THYMINE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031719211     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wang, M. C., Valenzuela, L. A., Murphy, G. P., and Chu, T. M. Purification of a human prostate specific antigen. Invest. Urol., 17: 159-163, 1979.
2. Lundwall, Å., and Lilja, H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett., 214: 317-322, 1987.
3. Nadji, M., Tabei, S. Z., Castro, A., Chu, T. M., Murphy, G. P., Wang, M. C., and Morales, A. R. Prostate-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (Phila.), 48: 1229-1232, 1981.
4. Papsidero, L. D., Kuriyama, M., Wang, M. C., Horoszewicz, J., Leong, S. S., Valenzuela, L., Murphy, G. P., and Chu, T. M. Prostate antigen: a marker for human prostate epithelial cells. J. Natl. Cancer Inst., 66: 37-41, 1981.
5. Qiu, S-D., Young, C. Y-F., Bilhartz, D. L., Prescott, J. L., Farrow, G. M., He, W-W., and Tindall, D. J. In situ hybridization of prostate-specific antigen mRNA in human prostate. J. Urol., 144: 1550-1556, 1990.
6. Young, C. Y-F., Montgomery, B. T., Andrews, P. E., Qiu, S., Bilhartz, D. L., and Tindall, D. J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748-3752, 1991.
7. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and Redwine, E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 377: 909-916, 1987.
8. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L., and Lange, P. H. Screening for prostatic carcinoma with prostate specific antigen. J. Urol., 147: 841-845, 1992.
9. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A., and Yang, N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076-1083, 1989.
10. Hakalahti, L., Vihko, P., Henttu, P., Autio-Harmainen, H., Soini, Y., and Vihko, R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer, 55: 590-597, 1993.
11. Sakai, H., Yogi, Y., Minami, Y., Yushita, Y. Kanetake, H., and Saito, Y. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J. Urol., 149: 1020-1023, 1993.
12. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M., and Scardino, P. T. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol., 151: 1558-1564, 1994.
13. Koji, T., and Nakane, P. K. Recent advances in molecular histochemical techniques: In situ hybridization and southwestern histochemistry. J. Electron Microsc., 45: 119-127, 1996.
14. Yoshii, A., Koji, T., Ohsawa, N., and Nakane, P. K. In situ localization of ribosomal RNAs in a reliable reference for hybridizable RNA in tissue sections. J. Histochem. Cytochem., 43: 321-327, 1995.
15. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate, 4 (Suppl.): 129-138, 1992.
16. Gleason, D. F. Histologic grading and clinical staging of prostatic carcinoma, pp. 171-198. In: M. Tannenbaum (ed.), Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger, 1977.
17. Zhou, A. M., Tewari, P. C., Bluestein, B. I., Caldwell, G. W., and Larsen, F. L. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin. Chem., 39: 2483-2491, 1993.
18. Kuriyama, M., Akimoto, S., Akaza, H., Arai, Y., Usami, M., Imai, K., Tanaka, Y., Yamazaki, H., Kawada, Y., Koiso, K., Yoshida, O., Kotake, T., Yamanaka, H., Machida, T., Aso, Y., and Shimazaki, J. Comparison of various assay systems for prostate-specific antigen standardization. Jpn. J. Clin. Oncol., 22: 393-399,1992.
19. Shinoda, I., Kuriyama, M., Takahashi, Y., Nagatani, Y., Kobayashi, S., Yamamoto, N., Kawamoto, S., Takeda, A., Iwata, H., Takeuchi, T., Shimazu, R., Tei, K., and Kawada, Y. Clinical evaluation of a chemiluminescence immunoassay for detection serum PSA. Jpn. J. Urol. Surg., 5: 1059-1064, 1992.
20. Schulz, P., Stucka, R., Feldmann, H., Combriato, G., Klobeck, H-G., and Fittler, F. Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leader sequence. Nucleic Acids Res., 16: 6226, 1988.
21. Tsurusaki, T., Koji, T., Hideki, S., Kanetake, H., Nakane, P. K., and Saito, Y. Cellular expression of β-microseminoprotein (β-MSP) mRNA and its protein in untreated prostate cancer. Prostate, 35: 109-116, 1998.
22. Henttu, P., Lukkarinen, O., and Vihko, P. Expression of the gene cording for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int. J. Cancer, 45: 654-660, 1990.
23. Koji, T., Chedid, M., Rubin, J. S., Slayden, O. D., Csaky, K. G., Aaronson, S. A., and Brenner, R. M. Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J. Cell Biol., 125: 393-401, 1994.
24. Pang, S., Taneja, S., Dardashti, K., Cohan, P., Kaboo, R., Sokoloff, M., Tso, C-L., deKernion, J. B., and Belldegrun, A. S. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther., 6: 1417-1426, 1995.
25. Baffa, R., Moreno, J. G., Monne, M., Veronese, M. L., and Gomella, L. G. A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostate tissue. Urology, 47: 795-800, 1996.
26. Hsieh, J-T., Wu, H-C., Cleave, M. E., von Eschenbach, A. C., and Chung, L. W. K. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res., 53: 2852-2857, 1993.
27. Henttu, P., Liao, S. S., and Vihko, P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acids (mRNA), but down-regulate the prostatic acids phosphatase mRNA in the LNCaP cell line. Endocrinology, 130: 766-772, 1992.
28. Dahiya, R., Park, H. D., Cusick, J., Vessella, R. L., Fournier, G., and Narayan, P. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int. J. Cancer, 59: 126-132, 1994.
29. Sokoloff, M. H., Tso, C-L., Kaboo, R., Taneja, S., Pang, S., deKernion, J. B., and Belldegrun, A. S. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (Phila.), 77: 1862-1872, 1996.
30. Thalmann, G. N., Sikes, R. A., Chang, S-M., Johnston, D. A., von Eschenbach, A. C., and Chung, L. W. K. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst., 88: 794-801, 1996.